Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Hearing On IP Policy: Patent Eligibility Requirements Are Top Industry Concern

Executive Summary

Supreme Court decisions on subject matter patentability have discouraged investments, panelists tell FTC; BIO says biotech companies may look outside patent system.

You may also be interested in...



I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter

The Initiative for Medicines, Access & Knowledge has responded to criticisms leveled by North Carolina senator Thom Tillis at a report it published in 2018. The report accuses pharmaceutical firms of using patent thickets to suppress generic and biosimilar competition in the US market.

US FDA, PTO Pulled Into Debate Over Patents And Drug Pricing

Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.

US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics

BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel